Eastern Vascular Society
EVS Home    |    Contact

Annual Meeting Home
 
Final Program
 
Past & Future Meetings

Back to 2016 Annual Meeting


Outcomes of Iliac Vein Stents Following Pregnancy
Mohini Dasari, BS1, Efthymios D. Avgerinos, MD1, Seshadri Raju, MD2, Robert Tahara, MD3, Rabih A. Chaer, MD1.
1University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, 2Rane Center for Venous and Lymphatic Disease, Jackson, MS, USA, 3Allegheny Vein & Vascular, Bradford, PA, USA.

Objective(s): Stenting is the first-line treatment for obstructive iliocaval lesions that are chronic or uncovered after thrombolysis of acute deep vein thrombosis (DVT). The aim of the study was to evaluate iliocaval stent patency in women of reproductive age.
Methods: Female patients of reproductive age (18-45 years old) who underwent iliocaval stenting between May 2007 and March 2014 were identified from a three-center prospectively-maintained database. Medical records were reviewed for demographics, baseline risk factors, operative data and clinical follow up to identify pregnancy and post-partum stent imaging. The endpoint was stent patency. Standard descriptive statistics were used.
Results: 45 women of reproductive age received iliocaval stenting; 12 were identified to have at least one pregnancy post-stenting. The mean age was 28 ± 5.0 years. One patient received treatment intrapartum for MTS, 3 for post-partum DVT, 3 with history of Factor V Leiden, and the rest for unprovoked DVT. All stents were self-expanding with a diameter range of 14-16mm. Mean time from stenting to pregnancy was 23.3 ± 28 months. All patients had patent stents during pregnancy and were placed on low molecular weight heparin. One had asymptomatic left-sided stent compression 1 year following her second delivery, treated with balloon dilatation. At average follow-up of 46 ± 56 months, all patients had patent stents with no ultrasonographically identified structural damage.
Conclusions: Pregnancy does not negatively impact the outcomes of iliocaval stents following DVT lysis of DVT or MTS. Iliocaval stenting is not contraindicated in women of reproductive age though close follow up is warranted.


Back to 2016 Annual Meeting